Zurich Cantonal Bank
TARS icon

Zurich Cantonal Bank’s Tarsus Pharmaceuticals TARS Stock Holding History

Zurich Cantonal Bank’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$571K Buy
9,067
+168
+2% +$10.7K ﹤0.01% 1871
2026
Q1 		$624K Buy
8,899
+1,308
+17% +$91.4K ﹤0.01% 1714
2025
Q4 		$622K Hold
7,591
– – ﹤0.01% 1648
2025
Q3 		$451K Buy
7,591
+1,836
+32% +$90.4K ﹤0.01% 1799
2025
Q2 		$233K Buy
5,755
+936
+19% +$42.1K ﹤0.01% 2060
2025
Q1 		$248K Sell
4,819
-1,002
-17% -$49.5K ﹤0.01% 1981
2024
Q4 		$322K Sell
5,821
-254
-4% -$11.5K ﹤0.01% 1897
2024
Q3 		$200K Sell
6,075
-34
-0.6% -$956 ﹤0.01% 2109
2024
Q2 		$166K Buy
6,109
+1,530
+33% +$51.4K ﹤0.01% 2129
2024
Q1 		$166K Sell
4,579
-727
-14% -$21.4K ﹤0.01% 2152
2023
Q4 		$107K Hold
5,306
– – ﹤0.01% 2410
2023
Q3 		$94.3K Buy
5,306
+2,092
+65% +$37K ﹤0.01% 2378
2023
Q2 		$58.1K Buy
+3,214
New +$51.1K ﹤0.01% 2561

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Zurich Cantonal Bank's TARS Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Tarsus Pharmaceuticals (TARS) stake by 1.9% in Q2 2026, buying an estimated $10.7K and bringing the position to 9,067 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Zurich Cantonal Bank first reported a position in TARS in Q2 2023 and has held it in 13 quarters since. The position peaked at $624K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Zurich Cantonal Bank held 9,067 shares of Tarsus Pharmaceuticals worth $571K as of Q2 2026.
  • Zurich Cantonal Bank bought 168 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $10.7K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1871 holding.
  • Zurich Cantonal Bank first reported a position in Tarsus Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Zurich Cantonal Bank's Tarsus Pharmaceuticals position peaked at $624K in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.